Literature DB >> 23922004

T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.

Richard B Thompson1, Kelvin Chow, Aneal Khan, Alicia Chan, Miriam Shanks, Ian Paterson, Gavin Y Oudit.   

Abstract

BACKGROUND: Fabry disease (FD) is an X-linked disorder of lysosomal metabolism affecting multiple organs with cardiac disease being the leading cause of death. Current imaging evaluations of the heart are suboptimal. The goals of the current study are to evaluate the potential of quantitative T₁ mapping with cardiovascular MRI as a disease-specific imaging biomarker. METHODS AND
RESULTS: A total of 31 patients with FD, 23 healthy controls, and 21 subjects with concentric remodeling or hypertrophy underwent cardiovascular MRI to measure left ventricular (LV) morphology, function, delayed enhancement, as well as myocardial T₁ values, and derived parameters (extracellular volume). All subjects had LV ejection fraction >50% and similar volumes. FD and concentric remodeling or hypertrophy had similarly increased mass, wall thickness, and mass/volume as compared with controls. A total of 16 of 31 FD subjects and 10 of 21 concentric remodeling or hypertrophy subjects had LV hypertrophy. Noncontrast myocardial T₁ values were substantially lower in FD as compared with controls and concentric remodeling or hypertrophy (1070 ± 50, 1177 ± 27, and 1207 ± 33 ms, respectively; P<0.001), but extracellular volume was similar in all groups (21.7 ± 2.4%, 22.2 ± 3.1%, and 21.8 ± 3.9%, respectively). Single-voxel NMR spectroscopy in 4 FD and 4 healthy control subjects showed a significant negative linear relationship between lipid content and noncontrast T₁ values (r=-0.9; P=0.002). Female subjects had lower LV mass and wall thickness, longer myocardial T₁ values and larger extracellular volume suggesting a key sex difference in cardiac remodeling.
CONCLUSIONS: Reduced noncontrast myocardial T₁ values are the most sensitive and specific cardiovascular MRI parameter in patients with FD irrespective of sex and LV morphology and function.

Entities:  

Keywords:  CMR; Fabry disease; cardiomyopathies; hypertrophy

Mesh:

Year:  2013        PMID: 23922004     DOI: 10.1161/CIRCIMAGING.113.000482

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  58 in total

Review 1.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.

Authors:  Clotilde Chatre; François Roubille; Hélène Vernhet; Christian Jorgensen; Yves-Marie Pers
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

3.  Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.

Authors:  Brendan N Putko; Haran Yogasundaram; Kelvin Chow; Joseph Pagano; Aneal Khan; D Ian Paterson; Richard B Thompson; Gavin Y Oudit
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-03-06       Impact factor: 6.875

4.  Point estimate and reference normality interval of MRI-derived myocardial extracellular volume in healthy subjects: a systematic review and meta-analysis.

Authors:  Francesco Sardanelli; Simone Schiaffino; Moreno Zanardo; Francesco Secchi; Paola Maria Cannaò; Federico Ambrogi; Giovanni Di Leo
Journal:  Eur Radiol       Date:  2019-05-02       Impact factor: 5.315

Review 5.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

Review 6.  PET/MR: Yet another Tesla?

Authors:  Markus Schwaiger; Karl Kunze; Christoph Rischpler; Stephan G Nekolla
Journal:  J Nucl Cardiol       Date:  2016-09-22       Impact factor: 5.952

Review 7.  Clinical applications of multiparametric CMR in left ventricular hypertrophy.

Authors:  Sabrina Nordin; Luke Dancy; James C Moon; Daniel M Sado
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-03       Impact factor: 2.357

8.  The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure.

Authors:  Mark A Peterzan; Oliver J Rider; Lisa J Anderson
Journal:  Card Fail Rev       Date:  2016-11

Review 9.  Redefining the role of biomarkers in heart failure trials: expert consensus document.

Authors:  Frank Kramer; Hani N Sabbah; James J Januzzi; Faiez Zannad; J Peter van Tintelen; Erik B Schelbert; Raymond J Kim; Hendrik Milting; Richardus Vonk; Brien Neudeck; Richard Clark; Klaus Witte; Wilfried Dinh; Burkert Pieske; Javed Butler; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 10.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.